TruGraf: A Blood-Based Gene Expression Assay for Kidney Transplant Monitoring

A manuscript details the development and commercialization of TruGraf, a clinically validated, blood-based gene expression assay. The assay aims to detect subclinical acute rejection in kidney transplant recipients with stable renal function, offering a non-invasive alternative to surveillance biopsies. The work was authored by M. Roy First from ID Genomics in the United States.

Use Cases

• Developing models to predict subclinical acute rejection based on blood-based gene expression profiles.
• Comparing the performance of non-invasive biomarkers against the gold-standard biopsy method.
• Studying the challenges of translating a biomarker assay from research to clinical commercialization.

Strengths

• Describes a clinically validated biomarker assay.
• Focuses on a specific and significant clinical problem: subclinical acute rejection in kidney transplants.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• Last update date is unknown; freshness unverified.

Provenance

Source

ID Genomics (United States)

Collection Method

Described in a manuscript detailing real-life development and commercialization challenges.